人参皂苷Re (98%, HPLC)
收藏
产品编号 SM6036-100mg
数量
¥ 401.00
产品包装:
10mM×0.2ml 25mg 100mg
产品简介
使用说明
相关文件下载
相关产品
相关论文
产品问答

化学信息:

中文名 人参皂苷Re
英文名 Ginsenoside Re
中文别名 -
英文别名 Ginsenoside B2; Panaxoside Re; Sanchinoside Re
来源 人参Panax ginseng C. A. Meyer
化合物类型 萜类(Terpenoids)>三萜>达玛烷型四环三萜皂苷
化学式 C48H82O18
分子量 947.15
CAS号 52286-59-6
纯度 98%, HPLC
溶剂/溶解度 DMSO: ≥ 50 mg/ml (52.79 mM)
溶液配制 10mg加入1.06ml DMSO,或者每9.47mg加入1ml DMSO,配制成10mM溶液。

生物信息

产品描述 Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of JNK and NF-κB.
信号通路 -
靶点 NF-κB JNK - -
IC50 - - - - -
体外研究 Ginsenoside Re is a well-known traditional Chinese medicine, which decreases the β-site amyloid precursor protein cleaving enzyme 1 (BACE1) mRNA and protein levels and inhibits BACE1 activity in the N2a/APP695 cells. Ginsenoside Re also significantly increases the PPARγ protein and mRNA levels.To prevent Ginsenoside Re from having a cytotoxic effect on the N2a/APP695 cells, the cell viability is first determined by the MTT assay. The N2a/WT and N2a/APP695 cells are treated with increasing concentrations of Ginsenoside Re (0-200 µM) for 24 h. Ginsenoside Re concentrations under 100 µM do not affect the viability of the N2a/WT and N2a/APP695 cells, whereas the 150 µM Ginsenoside Re concentration markedly decreases the survival rate of the N2a/WT and N2a/APP695 cells. Incubation with Ginsenoside Re at a 200 µM concentration for 24 h reduces the viability of the N2a/WT and N2a/APP695 cells by 15.58% and 26.82%, respectively. These data indicate that Ginsenoside Re treatment within the range of 0-100 µM for 24 h is safe for the N2a/WT and N2a/APP695 cells (P>0.05).
体内研究 Ginsenoside Re reduces insulin resistance in 3T3-L1 adipocytes and high-fat diet (HFD) rats through inhibition of JNK and NF-κB activation. Intraperitoneal injection of lipopolysaccharide (LPS) at a dose of 20 mg/kg is lethal to mice, and 70% to 80% of the mice die within 60 h. However, pretreatment of the mice with Rg1 or Ginsenoside Re increases their survival rates in a dose-dependent manner. With the doses of Rg1 or Ginsenoside Re increase from 2.5 to 5 mg/kg, the survival rate is elevated from 60% to 90% (Rg1) or from 30% to 40% (Ginsenoside Re). All the mice administered Rg1 at a minimal dose of 10 mg/kg are protected from death compared to 80% survival of mice treated with an equal dose of Ginsenoside Re. To protect all the mice, 20 mg/kg Ginsenoside Re is needed. To investigate the anti-inflammatory potential of Rg1 and Ginsenoside Re, 1 mg/kg Rg1 or Ginsenoside Re is injected into rats and then challenged the animals with LPS. The injection procedure itself causes a transient stress-induced increase in body temperature of ~1.2°C in each group. Thereafter, LPS-challenged rats without pretreatment develope a robust biphasic fever, with the first peak reaching ~1.5°C at 2 h and the second peak reaching 1.8°C at 4 h. In contrast, the temperature changes for the Rg1-, Ginsenoside Re-, and TAK-242-treated groups are only 0.9, 1.2, and 0.8°C at 2 h and 1.3, 1.4, and 1.0°C at 4 h, respectively. Pretreatment with Rg1, Ginsenoside Re, or TAK-242 significantly attenuates LPS-induced alterations in body temperature.
临床实验 NCT00781534: Diabetes, Early Phase 1.
参考文献:

1. Cao G, et al. Eur J Pharmacol. 2016,793:101-108.

2. Su F, et al. Antimicrob Agents Chemother. 2015,59(9):5654-63.

3. Zhang Z, et al. Mol Endocrinol. 2008,22(1):186-95.

包装清单:
产品编号 产品名称 包装
SM6036-10mM 人参皂苷Re (98%, HPLC) 10mM×0.2ml
SM6036-25mg 人参皂苷Re (98%, HPLC) 25mg
SM6036-100mg 人参皂苷Re (98%, HPLC) 100mg
- 说明书 1份
保存条件:

-20℃保存,至少一年有效。固体粉末4℃保存,至少一个月有效。如果溶于非DMSO溶剂,建议分装后-80℃保存,预计6个月内有效。

注意事项:

本产品可能对人体有一定的毒害作用,请注意适当防护,以避免直接接触人体或吸入体内。

本产品仅限于专业人员的科学研究用,不得用于临床诊断或治疗,不得用于食品或药品,不得存放于普通住宅内。

为了您的安全和健康,请穿实验服并戴一次性手套操作。

使用说明:
1. 收到产品后请立即按照说明书推荐的条件保存。使用前可以在2,000-10,000g离心数秒,以使液体或粉末充分沉降至管底后再开盖使用。
2. 对于10mM溶液,可直接稀释使用。对于固体,请根据本产品的溶解性及实验目的选择相应溶剂配制成高浓度的储备液(母液)后使用。
3. 具体的最佳工作浓度请参考本说明书中的体外、体内研究结果或其它相关文献,或者根据实验目的,以及所培养的特定细胞和组织,通过实验进行摸索和优化。
4. 不同实验动物依据体表面积的等效剂量转换表请参考如下网页:
https://www.beyotime.com/support/animal-dose.htm
相关产品请点击如下按钮:
使用本产品的文献: